Episode 56: Killing Cancer Through Direct Injection

May 14, 2020
Christen Harm

Christen Harm is Pharmaceutical Executive's Associate Editor. Email her at charm@mmhgroup.com

,
Elaine Quilici

Elaine Quilici is Pharmaceutical Executive's Senior Editor. Email her at equilici@mmh.com

Pharmaceutical Executive

Lew Bender, founder of Intensity Therapeutics and the inventor of Intensity’s DfuseRx platform technology, discusses the technology that allows the company’s therapeutic products to be injected directly into solid tumors, this innovative process successfully kills tumors and activates an immune response to shut down cancer cells throughout the body.

Lew Bender, founder of Intensity Therapeutics and the inventor of Intensity’s DfuseRx platform technology, discusses the technology that allows the company’s therapeutic products to be injected directly into solid tumors, this innovative process successfully kills tumors and activates an immune response to shut down cancer cells throughout the body.

You can listen and/or download the episode on SoundCloud, or directly through iTunes, GooglePlay, Stitcher, and Overcast.

 

Related Content:

Editorial Podcasts